Rigel EVP reports 5,718-share stock disposition

Rigel Pharmaceuticals executive David A. Santos, EVP and Chief Commercial Officer, reported a disposition of common stock.

Rhea-AI Filing Summary

Rigel Pharmaceuticals executive David A. Santos, EVP and Chief Commercial Officer, reported a disposition of common stock. On 02/02/2026, he disposed of 5,718 shares of Rigel common stock at $36.01 per share in a transaction coded "F." After this transaction, he beneficially owned 46,986 shares, held directly. A footnote explains that this balance includes 1,000 shares acquired under the issuer's stock purchase plan.

Insider Trade Summary

Exercise Price or Tax Liability: 5,718 shares

Exercise Price or Tax Liability 1 txn

Insider Santos David A

Role EVP, Chief Commercial Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	5,718	$36.01	$206K

Holdings After Transaction: Common Stock — 46,986 shares (Direct)

Footnotes (1)

1. F1. Includes 1,000 shares acquired under the Issuer's stock purchase plan.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did David A. Santos report at RIGL?

David A. Santos reported a disposition of Rigel Pharmaceuticals common stock. On February 2, 2026, he disposed of 5,718 shares in a transaction coded “F,” and continued to hold 46,986 shares directly after the transaction, according to the Form 4.

How many Rigel (RIGL) shares did Santos dispose of and at what price?

Santos disposed of 5,718 shares of Rigel common stock at a reported price of $36.01 per share. This transaction was recorded as code “F” on the Form 4, reflecting a change in his non-derivative holdings on February 2, 2026.

How many Rigel (RIGL) shares does David A. Santos own after this Form 4?

After the reported transaction, Santos beneficially owned 46,986 shares of Rigel common stock directly. A footnote clarifies that this total includes 1,000 shares acquired through the issuer’s stock purchase plan, indicating ongoing participation in the company’s equity programs.

What does the footnote about 1,000 Rigel (RIGL) shares indicate?

The footnote states that Santos’s reported holdings include 1,000 shares acquired under the issuer’s stock purchase plan. This means a portion of his 46,986 directly held shares came from regular purchases through Rigel Pharmaceuticals’ employee stock purchase arrangement.

What is David A. Santos’s role at Rigel Pharmaceuticals (RIGL)?

David A. Santos serves as Rigel Pharmaceuticals’ Executive Vice President and Chief Commercial Officer. The Form 4 identifies him as an officer of the company, rather than a director or 10% owner, providing context for his reported equity holdings and transactions.

Was the reported Rigel (RIGL) transaction direct or indirect ownership?

The Form 4 classifies Santos’s ownership as direct, marked with “D” in the ownership form column. There is no indication of indirect holdings through entities or other accounts in the provided data, and no footnotes disclaiming beneficial ownership authority.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 04:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Santos David A

(Last) (First) (Middle)

RIGEL PHARMACEUTICALS, INC.

611 GATEWAY BLVD, SUITE 900

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		F		5,718	D	$36.01	46,986(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 1,000 shares acquired under the Issuer's stock purchase plan.

	/s/ Raymond Furey (Attorney-in-Fact)	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.